LIMK2

Across TCGA pan-cancer cohorts, LIMK2 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated LIMK2 data layer compared with 6 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher LIMK2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIMK2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and ESCA show a favorable association.

SCLC, HNSC, and ACC are the cancer types where LIMK2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.167	0.505	.002	84	view →
HNSC	OS	Median	II,III,IV	0.261	0.540	<.001	66	view →
ACC	DFS	Quartile	All	0.161	0.697	<.001	37	view →
LUSC	DFS	Tertile	II,III,IV	0.806	0.595	.001	30	view →
MESO	OS	Tertile	All	0.268	0.515	.002	30	view →
LGG	OS	Tertile	All	0.741	0.874	<.001	26	view →
ESCA	OS	Quartile	III,IV	0.728	0.305	<.001	24	view →
THYM	DFS	Quartile	II,III,IV	1.000	0.753	.004	18	view →
THCA	OS	Median	II,III,IV	0.930	1.000	.014	17	view →
READ	OS	Tertile	II,III,IV	1.000	0.316	.003	14	view →
LIHC	OS	Median	III,IV	0.250	0.460	.014	12	view →
KIRP	DFS	Median	II,III,IV	0.877	0.347	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

LIMK2–SCLC (DFS)

Open the SCLC breakdown →